Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 17090560.
- Also identified by PMC identifier 1693658.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To compare the effectiveness of an early switch to oral antibiotics with the standard 7 day course of intravenous antibiotics in severe community acquired pneumonia. Multicentre randomised controlled trial. Five teaching hospitals and 2 university medical centres in the Netherlands. 302 patients in non-intensive care wards with severe community acquired pneumonia. 265 patients fulfilled the study requirements. Three days of treatment with intravenous antibiotics followed, when clinically stable, by oral antibiotics or by 7 days of intravenous antibiotics. Clinical cure and length of hospital stay. 302 patients were randomised (mean age 69.5 (standard deviation 14.0), mean pneumonia severity score 112.7 (26.0)). 37 patients were excluded from analysis because of early dropout before day 3, leaving 265 patients for intention to treat analysis. Mortality at day 28 was 4% in the intervention group and 6% in the control group (mean difference 2%, 95% confidence interval -3% to 8%). Clinical cure was 83% in the intervention group and 85% in the control group (2%, -7% to 10%). Duration of intravenous treatment and length of hospital stay were reduced in the intervention group, with mean differences of 3.4 days (3.6 (1.5) v 7.0 (2.0) days; 2.8 to 3.9) and 1.9 days (9.6 (5.0) v 11.5 (4.9) days; 0.6 to 3.2), respectively. Early switch from intravenous to oral antibiotics in patients with severe community acquired pneumonia is safe and decreases length of hospital stay by 2 days. Clinical Trials NCT00273676 [ClinicalTrials.gov].
Medical subject headings
- Amoxicillin
- Anti-Bacterial Agents
- Cephalosporins
- Clavulanic Acid
- Community-Acquired Infections
- Pneumonia, Bacterial